Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure

Abstract

The apicidin derivative, API-D, is capable of reducing hypertrophy and, consequently, the transition to heart failure in mice subjected to TAC. Treatment with this substance, therefore, holds promise as an important therapeutic option for heart failure.